The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI).

Colorectal Neoplasms / pathology Combined Modality Therapy Cytoreduction Surgical Procedures Humans Hyperthermic Intraperitoneal Chemotherapy Mitomycin / therapeutic use Oxaliplatin / therapeutic use Peritoneal Neoplasms / secondary Practice Patterns, Physicians' / statistics & numerical data Randomized Controlled Trials as Topic Surveys and Questionnaires

CRS-HIPEC Colorectal peritoneal metastases HIPEC PRODIGE 7

Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

ISSN: 1532-2157

Titre abrégé: Eur J Surg Oncol

Pays: England

ID NLM: 8504356

Informations de publication

Date de publication:
11 2021

Historique:

received: 12 04 2021

accepted: 09 05 2021

pubmed: 23 5 2021

medline: 6 1 2022

entrez: 22 5 2021

Statut: ppublish

Résumé

The PRODIGE 7-trial investigated the additional value of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to cytoreductive surgery (CRS) for patients with colorectal peritoneal metastases (CPM). The results of PRODIGE 7 were presented at the 2018 ASCO meeting showing that 30 min oxaliplatin-based HIPEC did not improve overall survival. The current study investigated the impact of PRODIGE 7 on the worldwide practice of CRS and HIPEC. CRS-HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning the current CRS-HIPEC practice in their hospital and country, and were asked to appraise the effect of PRODIGE 7. The survey was completed by 18/19 experts. Although their personal opinions of CRS-HIPEC were barely influenced by PRODIGE 7, they reported a substantial impact on daily practice. This included a switch towards Mitomycin-C based HIPEC-regimens and prolongation of HIPEC perfusion time, a reduction in the number of referrals from non-HIPEC centers, a reduction in national consensus, the removal of HIPEC from national guidelines, and a reduced reimbursement rate. The PRODIGE 7 has had a major impact on the practice of CRS-HIPEC for CPM worldwide. HIPEC remains an attractive option with potential for control and eradication of disease and further studies into the optimal HIPEC-regimen are urgently needed. Meanwhile, given the complexity of the treatment of patients with CPM, and the proven benefits of optimal CRS, referral of patients with potentially resectable CPM to expert centers is recommended whilst the precise role of HIPEC is further evaluated.

Identifiants

DOI: 10.1016/j.ejso.2021.05.023 PMID: 34020808

pubmed: 34020808

pii: S0748-7983(21)00499-6

doi: 10.1016/j.ejso.2021.05.023

pii:

doi:

Substances chimiques

Oxaliplatin 04ZR38536J

Mitomycin 50SG953SK6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

2888-2892

Informations de copyright

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no competing interests to declare.